



4 May 2017

09:30	Registration, Tea and Coffee
10:15	Welcome and Introductions Professor Ali Tavassoli - <i>Chair of Scientific Committee</i> <i>University of Southampton, UK</i>
10:25	Session One Introduction Chair: Dr Tom Heightman <i>Astex Pharmaceuticals, Cambridge, UK</i>
10:30	DNA Bases beyond Watson and Crick Professor Dr Thomas Carell <i>Ludwig Maximilians Universitat Munchen, Germany</i>
11:15	Inducing Protein Degradation as a Therapeutic Strategy Professor Craig M Crews <i>Yale Center for Molecular Discovery, USA</i>
12:00	Posters and Lunch
13:30	Session Two Introduction Chair: Professor Ulrike Eggert <i>King's College London, UK</i>
13:35	From peripheral proteins to membrane motors – mass spectrometry comes of age Professor Dame Carol Robinson <i>University of Oxford, UK</i>
14:20	Targeting Druggable Nodes for Disease Therapy using Chemoproteomic Platforms Professor Daniel Nomura <i>University of California, Berkeley, USA</i>
15:05	Posters and Coffee
16:30	Session Three Introduction Professor Rob Field <i>John Innes Centre, UK</i>
16:35	Chemical Biology tools for discoveries in biology and disease Dr Carsten Schultz <i>EMBL Heidelberg, Germany</i>
17:20	The Power of Chemoselectivity: Functional Protein-Conjugates for Proteomic and Pharmaceutical Research Professor Christian Hackenberger <i>Leibniz-Institut für Molekulare Pharmakologie and Humboldt Universität zu Berlin, Germany</i>
18:05	Concluding Remarks Professor Tom Brown - <i>President of RSC Chemical Biology Interface Division</i> <i>University of Oxford, UK</i>
18:15	Poster Session and Wine Reception
19:30	Close of sessions